AzTrials
AzTrials

Periapical PeriodontitisNCT06023901

The Importance of Prostaglandin and Nitric Oxide Synthesis in Apical Periodontitis

A study testing Apical periodontitis in people with Periapical Periodontitis, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A total of 185 subjects were divided into three categories: AP group (n=85), CP group (n=50) and healthy control group (n=50). The AP group was divided into 3 subgroups according to abscess scoring (AS-PAI) based on the periapical index. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Periapical Periodontitis
What is being tested?
Apical periodontitis
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
185 participants
Where
1 siteTurkey (Türkiye)
Study dates
7 Jan 2021to 2 Aug 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Apical periodontitis (AP) and/or chronic periodontitis (CP)
  • Patients who had taken antibiotics and/or anti-inflammatory drugs within the last 6 months - - Without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study

Who cannot join

  • with pregnancy or lactation were also excluded.
  • with a history of using steroid or nonsteroidal anti-inflammatory drugs and high-dose biotin vitamin in the last 48 hours were excluded from the study.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Istanbul Medipol University, Faculty of Dentistry

    Istanbul, ESENLER, 34083

Other trials in Turkey (Türkiye)

About this study

Official title: The Importance of Mechanosensitive Cell Mediated Prostaglandin and Nitric Oxide Synthesis in the Pathogenesis of Apical Periodontitis: Comparative With Chronic Periodontitis

A total of 185 subjects were divided into three categories: AP group (n=85), CP group (n=50) and healthy control group (n=50). The AP group was divided into 3 subgroups according to abscess scoring (AS-PAI) based on the periapical index. The CP group was divided into 4 subgroups according to the periodontitis staging system (PSS). After recording the demographic and clinical characteristics of all participants, blood and gingival crevicular fluid (GCF) samples were taken. TNF-α, IL-10, PGE2 and NO levels were measured in these samples.

Read the detailed description
  • Study Design This study was conducted at a single center. In order to reach the planned sample size, approximately 1200 patients who applied to the Department of Endodontics of Istanbul Medipol University between June 2021 and May 2022 due to apical periodontitis (AP) and/or chronic periodontitis (CP) were recorded including their intraoral examination and demographic characteristics. As a result of the examination, 85 patients with only AP (AP group) and 50 patients with only CP (CP group), whose diagnosis was confirmed, were included in the study. Patients having both AP and P were excluded from the study. Patients who had taken antibiotics and/or anti-inflammatory drugs within the last 6 months and those with pregnancy or lactation were also excluded. In addition, those with a history of using steroid or nonsteroidal anti-inflammatory drugs and high-dose biotin vitamin in the last 48 hours were excluded from the study, as this may affect the results. A healthy control group of 50 volunteers without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study. Those included in the research groups; randomly selected from people with similar gender, age and weight characteristics.
  • Demographic-Clinical History Gender, age, body mass index (BMI), comorbidity status of all patients participating in the study were recorded. The patients' root canal treatment (RCT), dental crown, composite/amalgam fillings (CF), number of missing teeth (NMT) findings were obtained as a result of intraoral examination.
  • Periapical and Periodontal Disease Scoring All teeth present in the oral cavity were radiographed and the presence of radiolucent images associated with the periapical region and radiographic bone loss was assessed. Panoramic radiographs, in the study, were obtained using a digital panoramic unit (VistaPano S, Durr Dental AG, Germany), operating at 73kVp and 10 mA with 13500 milliseconds exposure time in standard mode. For periapical radiographs Carestream RVG 5200 (RVG; Carestream Health Inc, Atlanta, CA, USA) system was used with an x-ray unit, setting of 70 kV, 8 mA. The bisecting angle technique was applied in obtaining the periapical images. Then, the radiographs were analyzed with Kodak Dental Imaging Software. From radiographic evaluation of the teeth, the presence of periapical radiolucency without periodontal disease was considered sufficient for AP diagnosis. Abscess scoring (AS-PAI) based on the periapical index was performed as an indicator of disease progression within the AP group. For this scoring, the periapical index (PAI) scoring system,10 which is a scoring system for the radiographic evaluation of apical periodontitis, was used. Accordingly, the AP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.

Periodontal measurements, obtained for the study, consisted of the highest probing depths (in milimetres) recorded around six selected teeth per participant. In this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss < 4 teeth, and Stage 4: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss > 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.

  • Collection of Venous Blood and Gingival Crevicular Fluid (GCF) Fasting (8-10 hours) venous blood of all participants was taken from forearm antecubital/basic veins. After keeping the blood at room temperature for 30 minutes, it was centrifuged at 2500 xg for 10 minutes. After centrifugation, the upper serum of the tubes was separated. Hemolysis indices (HI) of the sera were measured to prevent optical interference. (Cobas 8000 Chemistry Analyzer, USA). Those with a hemolysis index greater than 50 (mg/dl Hb) were excluded from the study. Appropriate sera were stored at -80oC until the day of analysis. In addition to venous blood, gingival crevicular fluid (GCF) samples were also collected and were stored at -80oC under similar conditions. On the day of analysis, all serums and GCF were first allowed to dissolve slowly at +4 oC and then brought to room temperature before measurement.

Gingival crevicular fluid samples were taken prior to periodontal probing to avoid contamination by blood. To avoid contamination of the sample, patients were asked not to eat or drink anything for at least 30 minutes before the procedure. Three samples were taken from the mesial, distal and buccal surfaces of related tooth. The selected sites were isolated with cotton roll and supragingival plaque, if present, was removed using a curette to prevent saliva and/or plaque contamination. GCF was collected for 60 seconds using PerioPaper strips (OraFlow Inc., NY, USA) placed gently until slight resistance was felt. The three samples were pooled into Eppendorf tubes and then placed in the laboratory freezer at -80 °C for storage. Periopapers were thoroughly washed in 0.5 ml eppendorf Tubes (after subtracting the tare weight of the tube) with 100 µl of phosphate-buffered saline (PBS) using an automatic pipette. Blood-stained paper strips were removed from the samples. All GCF samples were weighed on a precision balance (Shimadzu Libror, Model AEG-220, Germany) and recorded. All samples were thoroughly mixed with a 15-20 sec vortex device (Heidolph Reax Top Vortex, Schwabach, Germany). This allowed GCF to pass into PBS. The paper strips were removed without contaminating the samples and the remaining extract was stored in the freezer until the working day. The results obtained on the study day were proportioned by weights/PBS.

  • Biochemical Analyzes TNF-α, IL-10, NO and PGE2 levels in the sera of all patients were measured in Microplate ELISA Reader (BioTek Epoch 2 Microplate ELISA Reader, USA) using the ELISA method. Due to the insufficient amount of sample (100 µl), only NO and PGE2 levels were measured in the GCF using the same ELISA kit.

Serum TNF-α, IL-10, NO and PGE2 levels were analyzed using ELISA plates whose wells were pre-coated with antibody (human TNF-α, IL-10, NO or PGE2). The sensitivity of TNF-α, IL-10, NO and PGE2 test kits (Bioassay Technology Laboratory, China) is 1.52 ng/L, 2.59 pg/mL, 1.12 µmol/L and 1.28 ng/L, measuring range 3-900 ng/L, respectively, 5-1500 pg/mL, 2-600 µmol/L and 2-600 ng/L, CV for all tests for intraassay and interassay were < 10%.

Being tested
Apical periodontitis
Keywords
Gingival crevicular fluid, Apical periodontitis, Chronic periodontitis
Medical subject headings
Periapical Periodontitis, Chronic Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Apical periodontitisDiagnostic test

    Also called Chronic periodontitis

    Radiography of the patients were taken. Blood samples were collected from those patient

Study groups in NCT06023901
Study groupRoleWhat they receive
85 patients with only apical periodontitis (AP group)ExperimentalAP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.
Receives: Diagnostic Test: Apical periodontitis
50 patients with only chronic periodontitis (CP group),ExperimentalIn this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss < 4 teeth, and Stage 4: CAL > 5 mm, RBL is extending to mid-third of root and beyond and tooth loss > 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.
Receives: Diagnostic Test: Apical periodontitis
A healthy control group of 50 volunteersNo interventioncontrol group. A healthy control group of 50 volunteers without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The inflammatory markers TNF-α, IL-1β, IL-6 and IL-10,17

    TNF-α, IL-1β, IL-6 and IL-10,17 were measured by ELISA analysis.

    Measured: Through study completion, an average of 1 year

  2. The biomarkers with protective functions such as PGE2 and NO2

    PGE2 and NO2 were measured by ELISA analysis.

    Measured: Through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Sep 2023
  2. Study start7 Jan 2021
  3. Primary completion2 Jan 2022
  4. Study completion2 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
185 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06023901
Sponsor's protocol ID
E-10840098-772.02-2860/344
Status last verified
Feb 2026
First submitted
29 Aug 2023
Last updated
27 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Apical periodontitis in people with Periapical Periodontitis, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The inflammatory markers TNF-α, IL-1β, IL-6 and IL-10,17 (time frame: Through study completion, an average of 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in